Alkermes plc - Asset Resilience Ratio
Alkermes plc (8AK) has an Asset Resilience Ratio of 8.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Alkermes plc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Alkermes plc's Asset Resilience Ratio has changed over time. See net assets of Alkermes plc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Alkermes plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Alkermes plc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €199.65 Million | 8.03% |
| Total Liquid Assets | €199.65 Million | 8.03% |
Asset Resilience Insights
- Limited Liquidity: Alkermes plc maintains only 8.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Alkermes plc Industry Peers by Asset Resilience Ratio
Compare Alkermes plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Alkermes plc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Alkermes plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.03% | €199.65 Million ≈ $233.41 Million |
€2.49 Billion ≈ $2.91 Billion |
-14.38pp |
| 2024-12-31 | 22.40% | €460.52 Million ≈ $538.40 Million |
€2.06 Billion ≈ $2.40 Billion |
+7.61pp |
| 2023-12-31 | 14.79% | €316.02 Million ≈ $369.46 Million |
€2.14 Billion ≈ $2.50 Billion |
-1.30pp |
| 2022-12-31 | 16.09% | €315.99 Million ≈ $369.43 Million |
€1.96 Billion ≈ $2.30 Billion |
+6.27pp |
| 2021-12-31 | 9.82% | €198.77 Million ≈ $232.38 Million |
€2.02 Billion ≈ $2.37 Billion |
-5.12pp |
| 2018-12-31 | 14.93% | €272.53 Million ≈ $318.62 Million |
€1.83 Billion ≈ $2.13 Billion |
+1.46pp |
| 2017-12-31 | 13.48% | €242.21 Million ≈ $283.17 Million |
€1.80 Billion ≈ $2.10 Billion |
-4.53pp |
| 2016-12-31 | 18.01% | €310.86 Million ≈ $363.42 Million |
€1.73 Billion ≈ $2.02 Billion |
-1.05pp |
| 2015-12-31 | 19.06% | €353.67 Million ≈ $413.48 Million |
€1.86 Billion ≈ $2.17 Billion |
-2.16pp |
| 2014-12-31 | 21.21% | €407.10 Million ≈ $475.95 Million |
€1.92 Billion ≈ $2.24 Billion |
+8.87pp |
| 2013-12-31 | 12.34% | €194.67 Million ≈ $227.59 Million |
€1.58 Billion ≈ $1.84 Billion |
-- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more